Dysport is intended for the symptomatic treatment of focal spasticity: upper extremities in adults, of the lower extremities in adults with lesions of the ankle joint after stroke or traumatic brain injury dynamic equinus deformity of the foot in children aged 2 yEars and Nose and older with cerebral palsy, therapy is carried out in specialized medical institutions. Dysport is intended for symptomatic treatment in adults spastic torticollis; blepharospasm’s; hemifacial spasm; primary hyperhidrosis of the armpits of severe degree, does not respond to the use of topical antiperspirant and antihydrotic agents. Dysport is intended for temporary improvement of moderate or severe form: globulyarnykh wrinkles (vertical wrinkle between the eyebrows) with a maximum of naseleni and / or lateral periorbital wrinkles ( “crow’s feet”) with maximum smile in adults under the age of 65, when the sharp severity of these wrinkles has a strong psychological impact on the patient.
active substance: Clostridium botulinum type A toxin-haemagglutinin complex
1 vial contains a complex of botulinum toxin type A-hemagglutinin 300 IU or 500 IU;
Disport Excipients: human albumin solution, lactose monohydrate.
Disport Dosage form
Powder for solution for injection.
Basic physical and chemical properties:
white lyophilized powder without visible impurities. After dissolution – a clear colorless solution without mechanical inclusions.
white lyophilized powder without impurities.
Muscle relaxants with a peripheral mechanism of action. Code ATX M0ZA X01.
The Clostridium botulinum type A toxin-haemagglutinin complex blocks peripheral cholinergic transmission at the neuromuscular synapse by presynaptic action at the site proximal to the acetylcholine release site. The toxin acts on the nerve ending, counteracting Ca2 + -dependent phenomena that lead to the release of the mediator. It does not affect postganglionic cholinergic transmission or postganglionic sympathetic transmission.
The action of the toxin involves the initial stage of binding, when the toxin attaches quickly and firmly to the presynaptic membrane. Further internalization takes place, during which the toxin crosses the presynaptic membrane without causing paralysis. Eventually, the toxin blocks the release of acetylcholine, disrupting the Ca2 + -dependent mechanism of its release, and thus reduces the potential of the end plate and leads to paralysis.
Dysport® is intended for symptomatic treatment of focal spasticity:
upper extremities in adults;
lower extremities in adults with ankle injuries after a stroke or traumatic brain injury;
dynamic equinus deformity of the foot in children over 2 years of age with cerebral palsy, therapy is carried out in specialized medical institutions.
upper extremities in children with cerebral palsy aged 2 years.
Dysport® is intended for symptomatic treatment in adults:
spastic crooked neck;
primary hyperhidrosis of the axillary cavities, which does not respond to the use of topical antiperspirants and antihydrotics.
Dysport® is designed to temporarily improve the moderate or severe form:
glabellar wrinkles (vertical wrinkles between the eyebrows) at maximum swelling and / or
lateral periorbital wrinkles (“goose bumps”) at maximum smile
in adults under the age of 65, when the sharp expression of these wrinkles has a strong psychological impact on the patient.
Dysport® is contraindicated:
in case of known hypersensitivity to the active substance or to the excipients of the drug;
in the presence of infection at the injection site;
in the presence of severe myasthenia gravis, Lambert-Eaton syndrome or amyotrophic lateral sclerosis.